On 21 March 2019, we published an article about Impression Healthcare which stated that the company’s cannabis product sales could start as late as 2022.

This was incorrect. We now understand that the first of the clinical trials will commence in two to three months’ time, with sales to start this year.

The article has been updated to reflect this.

Whilst we make every effort to ensure our articles are factually correct, in this particular instance we got it wrong.

We apologise to Impression Healthcare and its shareholders for having published the incorrect information.